To Shareholders

Interim Report for Fiscal Year Ending March 31, 2011

Eisai Co., Ltd.
http://www.eisai.co.jp/index-e.html

To Our Shareholders

I thank you sincerely for your ongoing support. Here, we provide an overview of the Company's operating performance during the first half of the fiscal year ending March 31, 2011.

F_psm L_grm
Bgpcarmp* Npcqgbclr _lb ACM
&Pcnpcqclr_rgtc Cvcasrgtc Md«acp'

Overview of Consolidated Financial Results

2 Amlqmjgb_rcb lcr q_jcq dmp rfc qgv+kmlrf ncpgmb clbcb Qcnrck `cp 1.* 0./.* ucpc ¢2/0*061 kgjjgml &2,2# glapc_qc wc_p ml wc_p',

2 Q_jcq md *Aricept** _l _lrg+?jxfcgkcp%q _eclr* glapc_qcb rm ¢/50*.41 kgjjgml* sn /.,1# wc_p ml wc_p, Q_jcq md *Pariet* &S,Q, `p_lb l_kc8 *Aciphex*'* _ npmrml nskn glfg`grmp* a_kc rm ¢5.*12. kgjjgml* bmul 2,/# wc_p ml wc_p, Q_jcq md mlamjmew+pcj_rcb npmbsarq glapc_qcb rm ¢17*3// kgjjgml* sn /,1# wc_p ml wc_p,

2 Mncp_rgle glamkc* mpbgl_pw glamkc _lb lcr glamkc _jj cvaccbcb pcqsjrq pcampbcb gl rfc q_kc ncpgmb md rfc npctgmsq «qa_j wc_p* bpgtcl `w glapc_qcb epmqq npm«r _q _ pcqsjr md fgefcp q_jcq _q ucjj _q gknpmtcb cd«agclaqcq gl qcjjgle* eclcp_j _lb _bkglgqrp_rgtc cvnclqcq,

Consolidated Financial Results (1)

Consolidated Financial Results (2)

Shareholder Return

Full year Six months ended September 30

Net Sales (Billions of yen)



R&D Expenses (Billions of yen)

Operating Income (Billions of yen)



Progress of the *Aricept* Franchise

Al ho gh he *Aricept* pa en e pire in he Uni ed S a e in No ember 2010, e ill con rib e o he ell-being of pa ien i h Al heimer' di ea e b offering ch indica ion and form la ion a *Aricept 5mg and 10mg tablets*, *Aricept 5mg and 10mg orally disintegrating tablets*, he *Aricept 23mg tablet*, a eekl ran dermal pa ch form la ion (nder re ie).

• Higher Dose *Aricept 23mg Tablet*

The ne higher do e *Aricept 23mg tablet* en on ale in he Uni ed S a e in A g 2010. Thi able i in ended for e in he ame manner a pre io onece-dail admini ra ion for he rea men of modera e o e ere Al heimer' di ea e. S die of he *Aricept 23mg tablet* demon ra ed igni can impro emen in cogni ion compared o *Aricept 10mg tablet*. Thi ne do age pro ide an addi ional rea men op ion.

• A Weekly Transdermal Patch Formulation *Aricept* (Once-Weekly Administration)

In Sep ember 2010, he U.S. Food and Dr g Admini ra ion (FDA) accep ed for re ie a Ne Dr g Applica ion (NDA) bmi ed b Teikok Pharma USA, Inc., for a eekl ran dermal pa ch form la ion of he Compan ' Al heimer' di ea e agen , *Aricept*. Thi dr g, hich repre en he r eekl ran dermal pa ch form la ion for he rea men of mild, modera e and e ere age of Al heimer' di ea e, i in ended o red ce he b rden on caregi er and famil member ho admini er dail medica ion o heir lo ed one .

Topics

• Anticancer Agent *Treakisym*

In Oc ober 2010, S mBio Pharmace ical Limi ed recei ed appro al in Japan of *Treakisym*, an an icancer agen , for he indica ion of rec rren or refrac or lo -grade non-Hodgkin' l mphoma and man le cell l mphoma. Ei ai ha in place an agreemen i h S mBio Pharmace ical o man fac re and marke he dr g in Japan.

• A Rapid-Acting Insulin Secretagogue *Glufast*

Ei ai la nched *Glufast* (Chine e brand name: *Kuai ru tuo*), a rapid-ac ing in lin ecre agog e, in China in Sep ember 2010. Thi dr g i indica ed for he impro emen of po prandial blood gl co e ran i ion in pe II diabe ic pa ien . *Glufast* lo er gl co e le el b re oring in lin ecre ion clo e o i na ral pa ern i h a fa er on e of ac ion han lfon l rea in lin ecre ion im lan .